EMA to Review Sotagliflozin as Potential Treatment for Type 1 Diabetes

11:54 EDT 2 Apr 2018 | Drug Discovery Development

News
The European Medicines Agency (EMA) has accepted for review Sanofi’s regulatory submission for sotagliflozin.
Contributed Author: 
Sanofi
Topics: 
Drug Pipeline

Original Article: EMA to Review Sotagliflozin as Potential Treatment for Type 1 Diabetes

More From BioPortfolio on "EMA to Review Sotagliflozin as Potential Treatment for Type 1 Diabetes"